Molecular Mechanism of KLF4 Up-regulating Keratin 17 Expression in Keratinocytes

ZHANG Shuai, TAN Yuan, YIN Xiu-qin, LUO Hong

Abstract

To explore the role of Kruppel-like factor 4 (KLF4) in the regulation of Keratin 17 (KRT17) expression, and to reveal the molecular mechanism of overexpression of KRT17 in psoriatic lesions.  Methods  The skin lesions of 18 patients with psoriasis vulgaris were taken as experimental group and 10 healthy persons as control group. Real time-PCR and Western blot were used to detect the expression of KLF4 in psoriasis and normal skin samples, and the changes of KRT17 expression in HaCat cells after transfection of KLF4 overexpression and EP300 interfering plasmid. ChIP-qPCR was used to detect KLF4 binding and histone H3 acetylation levels in the promoter region of KRT17 in psoriasis and normal skin samples, and the changes of KLF4 binding and histone H3 acetylation levels in the promoter region of KRT17 in HaCat cells after transfection of KLF4 overexpression and EP300 interfering plasmid. Co-IP detects the interaction between KLF4 and EP300.  Results  The expression level of KLF4, KLF4 binding level and histone H3 acetylation level in the promoter region of KRT17 in psoriasis group were significantly higher than those in normal group (P<0.01). Compared with the control group, the expression level of KRT17 was significantly higher after KLF4 overexpression (P<0.01). After KLF4 overexpression combined with EP300 interference, the expression level of KRT17 was significantly lower than that of KLF4 overexpression group (P<0.01), slightly lower than that of control group (P<0.05). Compared with the control group, the histone H3 acetylation level in KRT17 promoter region in KLF4 over-expression group was increased significantly (P<0.01). After KLF4 over-expression combined with EP300 interference, the acetylation level of histone H3 in KRT17 promoter region was significantly lower than that in KLF4 overexpression group (P<0.01) and control group (P<0.01). Co-IP confirmed that KLF4 and EP300 could form protein complexes.  Conclusion  Excessive KLF4 increases the level of histone H3 acetylation in KRT17 promoter region by synergistic EP300, and mediates the over-expression of KRT17 in psoriatic lesions.

 

Keywords: Psoriasis, Keratinocyte, Keratin 17, KLF4 / EP300

 

Full Text:

PDF


References


DENG Y， CHANG C， LU Q. The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol，2016，50(3): 377–389.

LOWES M A， SUAREZ-FARINAS M， KRUEGER J G. Immunology of psoriasis. Annu Rev Immunol，2014，32: 227–255.

ZHOU F， ZHU Z， GAO J， et al. NFKB1 mediates Th1/Th17 activation in the pathogenesis of psoriasis. Cell Immunol，2018，331: 16–21.

CAMPANATI A， ORCIANI M， LAZZARINI R， et al. TNF-alpha inhibitors reduce the pathological Th1 -Th17/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients. Exp Dermatol，2017，26(4): 319–324.

LI N， XU H， OU Y， et al. LPS-induced CXCR7 expression promotes gastric cancer proliferation and migration via the TLR4/MD-2 pathway. Diagn Pathol， 2019， 14(1): 3[2019-11-16]. https://doi.org/10.1186/s13000-019-0780-x.

ZHANG J， LI X， WEI J， et al. Gallic acid inhibits the expression of keratin 16 and keratin 17 through Nrf2 in psoriasis-like skin disease. Int Immunopharmacol，2018，65: 84–95.

JIN L， WANG G. Keratin 17: a critical player in the pathogenesis of psoriasis. Med Res Rev，2014，34(2): 438–454.

YANG L， JIN L， KE Y， et al. E3 ligase Trim21 ubiquitylates and stabilizes Keratin 17 to induce STAT3 activation in psoriasis. J Invest Dermatol，2018，138(12): 2568–2577.

FU M， WANG G. Keratin 17 as a therapeutic target for the treatment of psoriasis. J Dermatol Sci，2012，67(3): 161–165.

YANG L， FAN X， CUI T， et al. Nrf2 promotes keratinocyte proliferation in psoriasis through up-regulation of Keratin 6, Keratin 16, and Keratin 17. J Invest Dermatol，2017，137(10): 2168–2176.

SHEN Z， CHEN L， LIU Y F， et al. Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis. J Am Acad Dermatol，2006，54(6): 992–1002.

GHALEB A M， YANG V W. Kruppel-like factor 4 (KLF4): what we currently know. Gene，2017，611: 27–37.

KUNES P， HOLUBCOVA Z， KREJSEK J. Occurrence and significance of the nuclear transcription factor Kruppel-like factor 4 (KLF4) in the vessel wall. Acta Medica (Hradec Kralove)，2009，52(4): 135–139.

HALIM S， MARKERT E K， VAZQUEZ A. Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer. Br J Cancer，2018，119(7): 855–863.

FEINBERG M W， CAO Z， WARA A K， et al. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem， 2005，280(46): 38247–38258.

KAUSHIK D K， THOUNAOJAM M C， KUMAWAT K L， et al. Interleukin-1beta orchestrates underlying inflammatory responses in microglia via Kruppel-like factor 4. J Neurochem，2013，127(2): 233–244.

TANG X， TIAN X， ZHANG Y， et al. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol，2013，2013: 345347[2019-11-16]. https://doi.org/10.1155/2013/345347.

CHOI S， LEE K， JUNG H， et al. Kruppel-like factor 4 positively regulates autoimmune arthritis in mouse models and rheumatoid arthritis in patients via modulating cell survival and inflammation factors of fibroblast-like synoviocyte. Front Immunol，2018，9: 1339[2019-11-16]. https://doi.org/10.3389/fimmu.2018.01339.

SHAHBAZIAN M D， GRUNSTEIN M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem，2007，76: 75–100.

COSTELLOE T， LOWNDES N F. Chromatin assembly and signalling the end of DNA repair requires acetylation of histone H3 on lysine 56. Subcell Biochem，2010，50: 43–54.

MCMANUS K J， HENDZEL M J. The relationship between histone H3 phosphorylation and acetylation throughout the mammalian cell cycle. Biochem Cell Biol，2006，84(4): 640–657.

OZDEMIR A， MASUMOTO H， FITZJOHN P， et al. Histone H3 lysine 56 acetylation: a new twist in the chromosome cycle. Cell Cycle，2006， 5(22): 2602–2608.

HENRY R A， KUO Y M， ANDREWS A J. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4. Biochemistry，2013，52(34): 5746–5759.

DAS C， LUCIA M S， HANSEN K C， et al. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature，2009，459(7243): 113–117.

CRUMP N T， HAZZALIN C A， BOWERS E M， et al. Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP. Proc Natl Acad Sci U S A，2011， 108(19): 7814–7819.


Refbacks

  • There are currently no refbacks.